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Background
Novel developments in tumor-immunotherapy show
promising results in cancer therapy and might provide new
opportunities for neuroblastoma treatment. To define sui-
table immunological targets, it is crucial to understand the
role of the immune system and the mechanisms underly-
ing neuroblastoma-induced immune suppression. We pre-
viously demonstrated accumulation of pro-inflammatory
immune cells within tumor tissues and effective anti-
inflammatory treatment with low-dose aspirin in the
TH-MYCN mouse model. This model can be further used
to dissect detailed mechanisms of neuroblastoma-induced
immune suppression relevant for tumor development and
tumor progression with the overall aim to define suitable
targets for neuroblastoma immunotherapy.
Methods
Flow-cytometric analysis of tumor tissues and spleens
were performed, as well as in vitro coculture assays with
splenocytes of neuroblastoma-bearing TH-MYCN mice.
Immune-cell status and functions were compared to
wildtype controls. Reagents targeting immune suppressive
mechanisms were tested in vitro. Coculture-assays using
tumor supernatant-treated bone marrow cells were estab-
lished to define factors responsible for the induction of
suppressive immune cells.
Results
Neuroblastoma-bearing animals develop splenomegaly,
indicating an active role of the peripheral immune system
during MYCN-driven neuroblastoma development. Flow-
cytometric analysis of spleens showed accumulation of
CD11b+Ly6c+Ly6g+ myeloid-derived suppressor cells
(MDSC) in tumor-bearing mice compared to controls.
The myeloid cell populations found in tumor-bearing ani-
mals expressed high levels of PD1-binding ligand, PD-L1,
suggesting a mechanism of T-cell inhibition and a possible
target for immunotherapy. In spleens, total T cell numbers
were reduced, while the CD4/CD8 ratio and expression of
activation markers remained unchanged. RegulatoryT cells
were present in tumor tissues, but their frequency was not
enhanced in spleens of cancer-bearing animals, indicating
that MDSCs play a major role in peripheral immune sup-
pression and tumor progression. Sorted from spleens of
tumor-bearing mice, these MDSCs were capable of sup-
pressing T cell proliferation in vitro through the produc-
tion of indolamine-2,3-dioxygenase (IDO) and inducible
nictric oxide synthase (iNOS). To dissect the mechanisms
of MDSC-induction in neuroblastoma, naïve bone marrow
cells were cultured with neuroblastoma tumor cell line
supernatants. This led to the development of suppressive
cells with an “MDSC-like” phenotype. This system will be
further exploited to define key factors enhancing the accu-
mulation of MDSCs in this malignancy.
Conclusions
Tumor-promoting inflammation contributes to neuroblas-
toma tumor development with active involvement of the
peripheral immune system. Further studies are needed to
define factors of the tumor microenvironment inducing
direct or indirect immune-suppression. Immunological
interventions by targeting various suppressive mechanisms
will be evaluated aiming at future clinical therapeutic
application.
1Karolinska Institutet, Stockholm, Sweden
Full list of author information is available at the end of the article
Eissler et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P203
http://www.immunotherapyofcancer.org/content/2/S3/P203
© 2014 Eissler et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ details
1Karolinska Institutet, Stockholm, Sweden. 2University of Tromsö, Tromsö,
Norway.
Published: 6 November 2014
doi:10.1186/2051-1426-2-S3-P203
Cite this article as: Eissler et al.: Immune suppression by myeloid-
derived suppressor cells, MDSCs, in MYCN-driven neuroblastoma
provides a potential target for cancer immunotherapy. Journal for
ImmunoTherapy of Cancer 2014 2(Suppl 3):P203.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Eissler et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P203
http://www.immunotherapyofcancer.org/content/2/S3/P203
Page 2 of 2
